miR-182-5p combined with brain-derived neurotrophic factor assists the diagnosis of chronic heart failure and predicts a poor prognosis

Figures

• 

  Fig. 1. miR-182-5p was upregulated in the serum of CHF patients. RT-qPCR was used to detect: A the expression of miR-182-5p in the serum of CHF patients and controls; B miR-182-5p expression in the serum of CHF patients with different NYHA functional stages. Data were as mean ± SD and independent unpaired t test was adopted for comparisons between two groups. **P < 0.01, ***P < 0.001

• 

  Fig. 2. Analysis of BDNF expression and its correlation with miR-182-5p in CHF patients. A The binding sites of miR-182-5p to BDNF were predicted by Starbase database; B The targeted binding of miR-182-5p and BDNF was validated using dual-luciferase assay; C BDNF expression in the serum of CHF patients and controls was determined via ELISA; D The correlation between miR-182-5p and BDNF in CHF patients was analyzed by Pearson assay. Data were expressed as mean ± SD and independent unpaired t test was used for comparisons between two groups. **P < 0.01

• 

  Fig. 3. Correlation analysis of serum miR-182-5p/BDNF with BNP and LVEF in CHF patients. In CHF patients, the Pearson method was employed to analyze: A the correlation of miR-182-5p and BDNF; B the association between miR-182-5p and LVEF; C the relevance of BDNF and BNP; D the relation between BDNF and LVEF

• 

  Fig. 4. miR-182-5p combined with BDNF had high diagnostic efficacy for CHF. ROC curve was plotted to analyze the diagnostic efficacy for CHF of: A serum miR-182-5p; B serum BDNF; C miR-182-5p combined with BDNF; D MedCalc assay was employed to analyze the AUC differences

• 

  Fig. 5. miR-182-5p high expression and BDNF low expression predicted poor prognosis in CHF. Kaplan–Meier curve was used to analyze the survival rate of miR-182-5p/BDNF high expression group and low expression group